International Agency for Research on Cancer, Lyon, France.
Taras Shevchenko National University of Kyiv, Ukraine.
J Cancer Policy. 2023 Dec;38:100436. doi: 10.1016/j.jcpo.2023.100436. Epub 2023 Aug 5.
Eastern Europe and Central Asia (EECA) countries have higher cervical and breast cancer mortality rates and later stage at diagnosis compared with the rest of WHO European Region. The aim was to explore current early detection practices including "dispensarization" for breast and cervix cancer in the region.
A questionnaire survey on early detection practices for breast and cervix cancer was sent to collaborators in 11 countries, differentiating services in the primary health setting, and population-based programs. Responses were received from Armenia, Belarus, Georgia, Kazakhstan, Kyrgyzstan, the Russian Federation (Arkhangelsk, Samara and Tomsk regions), Tajikistan, Ukraine, and Uzbekistan.
All countries but Georgia, Kyrgyzstan, and the Russian Federation had opportunistic screening by clinical breast exam within "dispensarization" program. Mammography screening programs, commonly starting from age 40, were introduced or piloted in eight of nine countries, organized at national oncology or screening centres in Armenia, Belarus and Georgia, and within primary care in others. Six countries had "dispensarization" program for cervix cancer, mostly starting from the age 18, with smears stained either by Romanowsky-Giemsa alone (Belarus, Tajikistan and Ukraine), or alternating with Papanicolaou (Kazakhstan and the Russian Federation). In parallel, screening programs using Papanicolaou or HPV test were introduced in seven countries and organized within primary care.
Our study documents that parallel screening systems for both breast and cervix cancers, as well as departures from evidence-based practices are widespread across the EECA. Within the framework of the WHO Initiatives, existing opportunistic screening should be replaced by population-based programs that include quality assurance and control.
东欧和中亚(EECA)国家的宫颈癌和乳腺癌死亡率以及诊断时的分期均高于世卫组织欧洲区域的其他国家。本研究旨在探索该地区目前的乳腺癌和宫颈癌早期检测实践,包括“分诊”。
向 11 个国家的合作者发送了一份关于乳腺癌和宫颈癌早期检测实践的问卷,区分了初级卫生保健环境中的服务和基于人群的方案。亚美尼亚、白俄罗斯、格鲁吉亚、哈萨克斯坦、吉尔吉斯斯坦、俄罗斯联邦(阿尔汉格尔斯克、萨马拉和托木斯克地区)、塔吉克斯坦、乌克兰和乌兹别克斯坦对此做出了回应。
除了格鲁吉亚、吉尔吉斯斯坦和俄罗斯联邦之外,所有国家都在“分诊”项目中开展了机会性乳腺检查筛查。九国中的八个国家引入或试点了乳腺钼靶筛查项目,这些项目通常从 40 岁开始,在亚美尼亚、白俄罗斯和格鲁吉亚的国家肿瘤学或筛查中心以及其他国家的初级保健机构中组织开展。六个国家开展了宫颈癌“分诊”项目,大多数从 18 岁开始,巴氏涂片或仅用瑞氏染色(白俄罗斯、塔吉克斯坦和乌克兰),或与巴氏涂片交替(哈萨克斯坦和俄罗斯联邦)。同时,七个国家引入了使用巴氏涂片或 HPV 检测的筛查方案,并在初级保健中组织开展。
本研究表明,EECA 国家广泛存在同时针对乳腺癌和宫颈癌的筛查系统,以及背离循证实践的情况。在世卫组织倡议框架内,应将现有的机会性筛查替换为包括质量保证和控制的基于人群的方案。